causal
CAR T-Cell Logistics Limit Scalability
CAR T-cell therapy requires extracting a patient's immune cells, flying them to a manufacturing site, gene-editing them, and flying them back within a short window because cell viability declines and the patients are gravely ill, which makes the process very hard to scale beyond niche use cases.
causalpending
Speaker
AlexEvidence Quote
“There's a lot of kinks in those processes that need to be ironed out before these technologies become scalable beyond these niche use cases.”
Source
Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the BestCreated: 11/14/2026, 6:42:06 AM
Your notes
Loading notes...